Welcome to the GHAPP Digital Hub

The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

The GHAPP Digital Hub is the place for all GI & Liver digital education for APPs. Here you will have access to podcasts and various short video modules.

Faculty

Alison Moe

PA-C

Atlanta, GA, USA

Elizabeth Goacher

PA-C, MHS

Raleigh, NC

Ann Moore

NP

Phoenix, AZ

Christina Hanson

FNP-C

South Denver Gastroenterology

Gabriella McCarty

NP-C

North Shore Gastroenterology

Tedra Gray

NP-C

Sinai Medical Group

Kimberly Orleck

PA-C

Atlanta Gastroenterology Associates

Kimberly Kearns

NP-C

DuPage Medical Group

Anne Feldman

NP

Cleveland Clinic Cleveland, OH

Corrie Berk

NP

The Texas Liver Institute

Podcasts

Implementing the IBS Guideline

The Clinical Utility of Guselkumab in CD

Simplifying Access: Prior Authorization Part 1

Simplifying Access: Prior Authorization Part 2

Simplifying Access: Evolving Drug Distribution Channels

GHAPPcast: The Clinical Utility of Guselkumab in UC

GHAPPcast Part 3: Provider & Patient Support

GHAPPcast Part 2: Diagnosis and Management

Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression

GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis

GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications

GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD

Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis

Building a Sense of Urgency for PBC Patient Evaluation/Monitoring

Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy

Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy

Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically

Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively

Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA

GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey

Webcasts

Navigating New Horizons: Evolutions of MASH Care

Post Conference MASH Highlights from AASLD

Post Conference MASH Highlights From ACG

Post Conference MASH Highlights From EASL

Post Conference MASH Highlights From DDW

Hot Topics in Chronic Liver Disease and Gi Disorders

Defining, Diagnosing, & Treating MASH

Lifestyle Modifications for Patients With MASH

Treatment of Metabolic Disorders and the Role of APPs in MASH

Updates On Approved Treatments for MASH

MASH Bootcamp Q&A

Identifying & Diagnosing MASH Patients with Non-Invasive Tests

2024 IBD Bootcamp

PBC New Therapeutic

Expert Perspectives on the Unmet Needs in Patients with Wilson Disease

FAQ Video Modules

What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?

How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?

How Does the Guselkumab Data Align With the STRIDE II Guidelines?

KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?

What Should Patients Know About Living With Cirrhosis?

What Are Predictive Risk Factors for Disease Severity in CD and UC?

What Lifestyle Changes Are Essential for Managing Cirrhosis Effectively?

How Can You Support a Shared Decision Making Process With the Patient?

How Can Physicians Better Care for Patients With Cirrhosis?

Is There a Correlation Between Myeloid Cells Expressing CD64 and Endoscopic Disease Severity?

Why Is Binding CD64+ Important When Discussing IL-23 Directed Therapy?

Provide Immunologic Rationale for IL-23 Directed Therapy in IBD

What Is the Role of the IL-23/IL-17 Axis in IBD?

Describe the IL-23/IL-17 Axis

Define, Compare, and Contrast Humoral and Cell-Mediated Immunity

Journal Club Video Modules

Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3

Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study

Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results

Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results

Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Medication Review Video Modules

What Is the Clinical Profile of Resmetirom, Including Dosing Schedules?

What Is Resmetirom and How Does It Work to Treat MASH?

Describe the Mechanism of Action of Guselkumab

What Is Non-Responder Imputation and How Is It Utilized in Clinical Trials?

How Is Guselkumab Dosed in IBD?

What Is the Safety Profile of Guselkumab in Ulcerative Colitis and Crohn's Disease?

What Is the Efficacy of Guselkumab in Ulcerative Colitis and Crohn's Disease?

What Are Guselkumab's Other FDA Indications and How Might That Affect Patient Care?

Publications

Emerging Strategies for Drug-Based Cancer Risk Reduction

Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases

Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database

Quantified motility in Crohn's disease to evaluate stricture composition using cine-MRI

Characterizing Crohn's disease phenotypes through pan-enteric capsule endoscopy

Factors Associated With Delayed Endoscopic Retrograde Cholangiopancreatography Among Patients With Acute Cholangitis

Molecular imaging of gastrointestinal stromal tumor using anti-c-KIT antibody and its fragments

Integrated hepatic ferroptosis gene signature dictates pathogenic features of ferroptosis

Meaningful differences in patient-reported outcome measurement scores in liver disease

Comparing the performance of 3 sarcopenia definitions for predicting adverse events prior to liver transplant

A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel framework

Exploration of the mechanism of Polyphyllin I against hepatocellular carcinoma based on network pharmacology, molecular docking and experimental validation

ASO Visual Abstract: Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens

Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors

The Enteric Microbiome in Early Onset Colorectal Cancer: A Comprehensive Review of its role as a Biomarker of Disease

sectionimg

dotimg

Download the app and start using it now

Download on the App Store

GET IT ON Google Play